TABLE 6.
Results from multivariable regression models for TRM score in discrete patient subsets
| Non-relapse mortality | Relapse | Relapse-free survival | Overall survival | |
|---|---|---|---|---|
| Subset of MAC HCT patients * | ||||
| TRM score (cont. variable) | 1.15 (1.08–1.22), P<0.001 | 1.05 (0.99–1.11), P=0.11 | 1.07 (1.02–1.12), P=0.002 | 1.07 (1.02–1.12), P=0.0022 |
| TRM score (quartiles) | ||||
| 1st quartile | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 2nd quartile | 1.65 (0.91–2.98), P=0.099 | 0.81 (0.54–1.23), P=0.32 | 1.03 (0.74–1.45), P=0.84 | 1.03 (0.72–1.46), P=0.89 |
| 3rd quartile | 2.08 (1.12–3.85), P=0.02 | 1.01 (0.66–1.54), P=0.96 | 1.28 (0.90–1.81), P=0.16 | 1.26 (0.88–1.82), P=0.21 |
| 4th quartile | 3.58 (1.90–6.75), P<0.001 | 1.06 (0.66–1.68), P=0.82 | 1.50 (1.02–2.18), P=0.037 | 1.50 (1.01–2.24), P=0.046 |
| Subset of non-MAC HCT patients * | ||||
| TRM score (cont. variable) | 1.10 (1.07–1.14), P<0.001 | 1.10 (0.96–1.05), P=0.87 | 1.05 (1.03–1.08), P<0.001 | 1.09 (1.06–1.12), P<0.001 |
| TRM score (quartiles) | ||||
| 1st quartile | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 2nd quartile | 1.71 (0.60–4.86), P=0.32 | 1.45 (0.64–3.31), P=0.38 | 1.59 (0.83–3.04), P=0.16 | 1.77 (0.88–3.54), P=0.11 |
| 3rd quartile | 2.88 (1.10–7.56), P=0.031 | 2.55 (1.19–5.45), P=0.016 | 2.76 (1.52–5.02), P<0.001 | 2.57 (1.35–4.90), P=0.0043 |
| 4th quartile | 3.69 (1.47–9.28), P=0.0056 | 1.71 (0.81–3.64), P=0.16 | 2.44 (1.36–4.36), P=0.0027 | 2.86 (1.52–5.36), P=0.0011 |
| Subset of 10/10 HLA-matched HCT patients ** | ||||
| TRM score (cont. variable) | 1.15 (1.09–1.22), P<0.001 | 1.02 (0.97–1.08), P=0.41 | 1.07 (1.03–1.11), P=0.0012 | 1.10 (1.05.−1.14), P<0.001 |
| TRM score (quartiles) | ||||
| 1st quartile | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 2nd quartile | 1.40 (0.72–2.75), P=0.32 | 1.06 (0.66–1.70), P=0.81 | 1.17 (0.79–1.72), P=0.43 | 1.33 (0.88–2.01), P=0.17 |
| 3rd quartile | 1.78 (0.90–3.51), P=0.096 | 1.44 (0.90–2.29), P=0.13 | 1.54 (1.05–2.26), P=0.026 | 1.53 (1.01–2.32), P=0.042 |
| 4th quartile | 2.75 (1.33–5.70), P=0.0064 | 1.40 (0.82–2.39), P=0.21 | 1.74 (1.13–2.68), P=0.012 | 2.07 (1.31–3.27), P=0.0018 |
Besides TRM score, models included karyotype/cytogenetic risk group at AML diagnosis, first vs. second remission at time of HCT, and pre-HCT MRD status.
Besides TRM score, models included gender, karyotype/cytogenetic risk group at AML diagnosis, first vs. second remission at time of HCT, pre-HCT MRD status, cytogenetics at time of HCT, HCT-CI/age composite score, PAM score, revised EBMT score, ANC recovery before HCT, platelet count recovery before HCT, donor type (related vs. unrelated), and conditioning intensity.
Abbreviations: ANC, absolute neutrophil count; HCT, hematopoietic cell transplantation; MAC, myeloablative conditioning; TRM, treatment-related mortality.